Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some hospitals that participate in a federal drug discount program. In its lawsuit, the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for its Xarelto blood thinner and the Stelara plaque psoriasis treatment.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
